Brian Van Tine, MD, PhD, on Bringing Cell Therapy Into Synovial Sarcoma Treatment
The professor medicine and pediatrics at Washington University in St. Louis overviewed data from the SPEARHEAD-1 trial of afami-cel.
“We work with AdaptImmune on the SPEAR T-cell, which is a modified T cell, where we look at patients that are HLA-A*0-positive and express MAGEA4. This was a trial that I've been working on since almost the very beginning of the phase 1 that was presented in 2017 at ESMO, and there's been multiple updates of the registrational phase 2which has enabled the therapy to be up for a biologics license application. At Tandem, I’m giving a talk to bone marrow transplantation doctors.”
Afamitresgene autoleucel (afami-cel; Adaptimmune Therapeutics) has continued to demonstrate continued clinical responses in patients with late-stage synovial sarcoma in the phase 2 SPEARHEAD-1 study (NCT04044768). Investigator Brian Van Tine, MD, PhD, professor medicine and pediatrics at Washington University in St. Louis, gave a talk on afami-cel, how its builds on the data seen so far in the field, and protocol changes to support implementation of cell therapy in sarcoma at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19.
CGTLive spoke with Van Tine to learn more about afami-cel and how it could potentially improve outcomes for patients with synovial sarcoma, a disease area that has previously not seen many novel therapies. He overviewed the data generated and how it has favorably matured.
For more coverage of the 2023 Tandem Meetings, click here.
